Analyst Rating Update on Alimera Sciences (ALIM)

Alimera Sciences (ALIM) : The consensus on Alimera Sciences (ALIM) based on 1 analyst recommendation on the company stock is 3, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

For the current week, the company shares have a recommendation consensus of Buy.


Alimera Sciences (NASDAQ:ALIM): The stock opened at $2.07 on Wednesday but the bulls could not build on the opening and the stock topped out at $2.09 for the day. The stock traded down to $1.90 during the day, due to lack of any buying support eventually closed down at $2.00 with a loss of -0.50% for the day. The stock had closed at $2.01 on the previous day. The total traded volume was 937,170 shares.

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye, or retina. The Companys commercial product is ILUVIEN, which has been developed to treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the EU countries, it is indicated for the treatment of vision impairment associated with DME.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.